JPH06506950A - 代用血液及び臓器保存溶液 - Google Patents
代用血液及び臓器保存溶液Info
- Publication number
- JPH06506950A JPH06506950A JP4511145A JP51114592A JPH06506950A JP H06506950 A JPH06506950 A JP H06506950A JP 4511145 A JP4511145 A JP 4511145A JP 51114592 A JP51114592 A JP 51114592A JP H06506950 A JPH06506950 A JP H06506950A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- sodium
- concentration
- specimen
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003633 blood substitute Substances 0.000 title description 23
- 239000000162 organ preservation solution Substances 0.000 title description 2
- 239000000243 solution Substances 0.000 claims description 227
- 210000004369 blood Anatomy 0.000 claims description 102
- 239000008280 blood Substances 0.000 claims description 102
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 39
- 239000011734 sodium Substances 0.000 claims description 38
- 235000002639 sodium chloride Nutrition 0.000 claims description 38
- 229910052708 sodium Inorganic materials 0.000 claims description 37
- 230000010412 perfusion Effects 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 30
- 239000001301 oxygen Substances 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 230000004087 circulation Effects 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 21
- -1 hexose monosaccharides Chemical class 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 17
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 239000011777 magnesium Chemical class 0.000 claims description 12
- 229910052749 magnesium Chemical class 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 230000008961 swelling Effects 0.000 claims description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 150000003841 chloride salts Chemical class 0.000 claims description 10
- 235000000346 sugar Nutrition 0.000 claims description 10
- 229920002307 Dextran Polymers 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 235000011148 calcium chloride Nutrition 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 8
- 229910001415 sodium ion Inorganic materials 0.000 claims description 8
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000176 sodium gluconate Substances 0.000 claims description 7
- 235000012207 sodium gluconate Nutrition 0.000 claims description 7
- 229940005574 sodium gluconate Drugs 0.000 claims description 7
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 claims description 7
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 239000000372 cardioplegic agent Substances 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 150000002402 hexoses Chemical class 0.000 claims 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 122
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 241000699800 Cricetinae Species 0.000 description 29
- 230000036760 body temperature Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 210000000056 organ Anatomy 0.000 description 20
- 238000001816 cooling Methods 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 13
- 210000001105 femoral artery Anatomy 0.000 description 12
- 238000005534 hematocrit Methods 0.000 description 12
- 229910001414 potassium ion Inorganic materials 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000003191 femoral vein Anatomy 0.000 description 10
- 238000004321 preservation Methods 0.000 description 10
- 241000288906 Primates Species 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960003299 ketamine Drugs 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 208000010496 Heart Arrest Diseases 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 241001504519 Papio ursinus Species 0.000 description 5
- 229940119744 dextran 40 Drugs 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000002847 Surgical Wound Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000037000 normothermia Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- WEQHQGJDZLDFID-UHFFFAOYSA-J thorium(iv) chloride Chemical compound Cl[Th](Cl)(Cl)Cl WEQHQGJDZLDFID-UHFFFAOYSA-J 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 241000282516 Papio anubis Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000008150 cryoprotective solution Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical class OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 229940027278 hetastarch Drugs 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 241000197727 Euscorpius alpha Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- CEALXSHFPPCRNM-UHFFFAOYSA-L disodium;carboxylato carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OC([O-])=O CEALXSHFPPCRNM-UHFFFAOYSA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000020673 hypertrichosis-acromegaloid facial appearance syndrome Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940043200 pentothal Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical class OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.多糖類の腫脹剤、生理学的に適合性のある緩衝液、ヘキソース単糖、カルシ ウムの、ナトリウムの及びマグネシウムの溶解性塩化物塩、並びにナトリウムの 溶解性有機塩を含んで成る水溶液。 2.上記のヘキソース単糖がグルコース、フルクトース及びガラクトースから成 るグループから選ばれる、請求項1の溶液。 3.前記の生理学的に適合性のある緩衝液がTris、Hepes、Mops、 Tham及びEps緩衝液から成るグループから選ばれる、請求項1の溶液。 4.前記の多糖類がデキストランである、請求項1の溶液。 5.上記のデキストランが約30.000から70,000ダルトンまでの範囲 の平均分子量をもつ、請求項4の溶液。 6、前記のデキストランが約40,000ダルトンの範囲の平均分子量をもつ、 請求項4の溶液。 7.前記のデキストランが重量/容量に基づき上記溶液の約8%を含んで成る、 請求項4の溶液。 8.前記の、カルシウムの、ナトリウムの及びマグネシウムの溶解性塩化物塩、 並びにナトリウムの溶解性有機塩から得られる、カルシウムイオン、ナトリウム イオン及びマグネシウムイオンの濃度が、血漿中のこれらのイオンの正常な生理 学的濃度の範囲内である、請求項1の溶液。 9.塩化ナトリウムの濃度が70mAlから約160Mまでの範囲内にあり、塩 化カルシウムの濃度が約0.5mM〜4.0mMの範囲内にあり、そして塩化マ グネシウムの濃度が0〜10mMの範囲内にある、請求項1の溶液。 10.塩化ナトリウムの濃度が約85〜95mMの範囲内にある、請求項9の溶 液。 11.塩化ナトリウムの濃度が約90mMである、請求項9の溶液。 12.塩化カルシウムの濃度か約1.5mM〜3.5mMの範囲内にある、請求 項9の溶液。 13.塩化カルシウムの濃度が約2mMである、請求項9の溶液。 14.塩化マグネシウムの濃度が約1mM〜10mMの範囲内にある、請求項9 の溶液。 15.塩化マグネシウムの濃度が約2mMである、請求項9の溶液。 16.前記のナトリウムの有機塩及び塩化ナトリウムから得られるナトリウムイ オンの濃度が、溶液のナトリウムイオンの濃度を生理学的に正常な血漿のナトリ ウムイオンについての濃度までもっていいくのに十分である、請求項1の溶液。 17.前記のナトリウムの有機塩が約5mM〜70mMの濃度範囲内のグルコン 酸ナトリウムである、請求項1の溶液。 18.上記のグルコン酸ナトリウムの濃度が約27mMである、請求項17の溶 液。 19.前記の生理学的に適合性のある緩衝液が、37℃で7.77のpKa及び −0.031のデルタpKa/0℃をもつ、請求項1の溶液。 20.Tris塩基の濃度が約25mMである、請求項1の溶液。 21.それらのpHが約25℃で約7.8である、請求項1の溶液。 22.それらの重量オスモル濃度が生理学的に正常な血漿のものにほぼ同じであ る、請求項1の溶液。 23,それらのモル濃度が290mM〜約330mMの範囲内にある、請求項1 の溶液。 24.それらのモル濃度が約298mMである、請求項1の溶液。 25.ヘキソース糖の濃度が約2mM〜200mMの範囲内にある、請求項2の 溶液。 26.ヘキソース糖の濃度が約200mMである、請求項2の溶液。 27.前記の溶液が無菌であり、そして無菌容器内に収められている、請求項1 の溶液。 28.腫脹剤、生理学的に適合性のある緩衝液、ヘキソース単糖、カルシウムの 、ナトリウムの及びマグネシウムの塩化物塩、並びにナトリウムの有機塩を含ん で成る乾燥無菌混合物。 29.無菌容器内に収められた請求項28の混合物。 30.低分子量の脂肪族ポリーアルコールをさらに含んで成る、請求項1の溶液 。 31.上記の低分子量の脂肪族ポリーアルコールがジオールである、請求項30 の溶液。 32.上記のジオールがエチレンジオール、プロパンジオール及びブタンジオー ルから成るグループから選ばれる、請求項31の溶液。 33.前記のジオールがプロパンジオールである請求項31の溶液。 34.上記のプロパンジオールが1.2−プロパンジオールである、請求項32 の溶液。 35.前記のプロパンジオールが0.2モル〜1モルの間の濃度範囲内にある、 請求項33の溶液。 36.上記のプロパンジオールが0.2モル〜0.6モルの間の濃度範囲内にあ る、請求項35の溶液。 37.前記のプロパンジオールが約0.4Mの濃度である、請求項35の溶液。 38.トリメチルアミンオキサイドをさらに含んで成る、請求項1の溶液。 39.上記のトリメチルアミンオキサイドが0.2〜7Mの濃度範囲内にある、 請求項38の溶液。 40、上記のトリメチルアミンオキサイドが約1Mの濃度である、請求項39の 溶液。 41.以下の段階: その検体の温度を正常より低い温度まで低下させ、心停止剤を投与することによ りその検体の心臓の鼓動を停止させ、多糖類の腫脹剤、生理学的に適合性のある 緩衝液、ヘキソース単糖、カルシウムの、ナトリウムの及びマグネシウムの溶解 性塩化物塩、並びにナトリウムの溶解性有機塩を含んで成る溶液を、上記の検体 の中に循環させ、そして、 次に、この検体に温かい血液を再注入する、を含んで成ることがそこに必要であ る循環の灌流の準備をされた検体を、灌流する方法。 42.以下の段階: その検体の温度を正常より低い温度まで低下させ、心停止剤を投与することによ りその検体の心臓の鼓動を停止させ、多糖類の腫脹剤、生理学的に適合性のある 緩衝液、ヘキソース単糖、カルシウムの、ナトリウムの及びマグネシウムの溶解 性塩化物塩、ナトリウムの溶解性有機塩、並びに低分子量の脂肪族ポリアルコー ルを含んで成る溶液を、上記の検体の中に循環させ、それが0℃未満に達するま でその検体の温度を更に低下させ、その検体の温度を0℃より高く上昇させ、そ して、次に、この検体に温かい血液を再注入する、を含んで成ることがそこに必 要である循環の灌流の準備をされた検体を、冷凍する方法。 43.上記の脂肪族ポリアルコールがプロパンジオールである、請求項42の方 法。 44.検体の温度を0℃より高く上昇させた後の、かつ、検体に温かい血液を再 注入することに先立つ、上記の検体中に、多糖類の腫脹剤、生理学的に適合性の ある緩衝液、ヘキソース単糖、カルシウムの、ナトリウムの及びマグネシウムの 溶解性塩化物塩、並びに、ナトリウムの溶解性有機塩を含んで成る溶液を循環さ せる追加の段階がある、請求項43の方法。 45.以下の段階: その検体の温度を正常より低い温度まで低下させ、その検体を高圧酸素雰囲気内 に置き、 多糖類の腫脹剤、生理学的に適合性のある緩衝液、ヘキソース単糖、カルシウム の、ナトリウムの及びマグネシウムの溶解性塩化物塩、並びにナトリウムの溶解 性有機塩を含んで成る溶液を、上記の検体の中に循環させ、そして、 次に、この検体に温かい血液を再注入する、を含んで成ることがそこに必要であ る循環の灌流の準備をされた検体を、灌流する方法。 46.以下の段階: その検体を高圧酸素雰囲気内に置き、 多糖類の腫脹剤、生理学的に適合性のある緩衝液、ヘキソース単糖、カルシウム の、ナトリウムの及びマグネシウムの溶解性塩化物塩、並びにナトリウムの溶解 性有機塩を含んで成る溶液を、上記の検体の中に循環させ、そして、 この検体を、その検体が正常な大気圧にて再び活動するのに十分な期間、上記の 高圧酸素雰囲気内で維持する、を含んで成ることがそこに必要である循環の灌流 の準備をされた検体を、維持する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68784191A | 1991-04-19 | 1991-04-19 | |
US687,841 | 1991-04-19 | ||
US86070392A | 1992-04-01 | 1992-04-01 | |
US860,703 | 1992-04-01 | ||
PCT/US1992/003240 WO1992018136A1 (en) | 1991-04-19 | 1992-04-17 | Blood substitutes and organ preservative solutions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06506950A true JPH06506950A (ja) | 1994-08-04 |
JP3133330B2 JP3133330B2 (ja) | 2001-02-05 |
Family
ID=27104094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP04511145A Expired - Lifetime JP3133330B2 (ja) | 1991-04-19 | 1992-04-17 | 代用血液及び臓器保存溶液 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5574019A (ja) |
EP (1) | EP0581883B1 (ja) |
JP (1) | JP3133330B2 (ja) |
AT (1) | ATE202937T1 (ja) |
CA (1) | CA2066374C (ja) |
DE (1) | DE69231929T2 (ja) |
ES (1) | ES2162797T3 (ja) |
IL (1) | IL101637A (ja) |
WO (1) | WO1992018136A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002302401A (ja) * | 2001-04-02 | 2002-10-18 | Okinawa Prefecture Deep Ocean Water Development Coop Society | 鮮度液及びその製造方法 |
JP2010531866A (ja) * | 2007-07-03 | 2010-09-30 | アキックス リミテッド | N−置換アミノスルホン酸緩衝剤を含んでなる体液増量剤 |
JP2018087154A (ja) * | 2016-11-28 | 2018-06-07 | 3C株式会社 | 保存装置および臓器移植方法 |
JP2020505351A (ja) * | 2017-01-17 | 2020-02-20 | エクスビボ パフュージョン アクチボラゲット | 臓器保存及び/又は灌流用溶液 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100301340B1 (ko) * | 1992-10-30 | 2001-10-22 | 알렉산드로비치 마르코프 제나디 | 생물체 표현형의 생물학적 자극및 교정을 위한 조성물 그리고 이것의 처리방법 |
AU681675B2 (en) * | 1993-06-04 | 1997-09-04 | Biotime, Inc. | Plasma-like solution |
US6680305B1 (en) | 1993-06-04 | 2004-01-20 | Biotime, Inc. | Physiologically acceptable aqueous solutions and methods for their use |
US6300322B1 (en) | 1993-06-04 | 2001-10-09 | Biotime, Inc. | Plasma-like solution |
CA2174806A1 (en) * | 1995-04-24 | 1996-10-25 | Frank Sever Jr. | Method and apparatus for enabling extracorporeal therapeutic treatment of a living patient's entire blood supply during a single uninterrupted time interval |
US6794124B2 (en) | 1995-12-15 | 2004-09-21 | Stiftelsen Facthor | Preservation solution |
SE505499C2 (sv) * | 1995-12-15 | 1997-09-08 | Stiftelsen Facthor | Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed |
US5843024A (en) * | 1996-05-17 | 1998-12-01 | Breonics, Inc. | Solution and process for resuscitation and preparation of ischemically damaged tissue |
US6743575B2 (en) | 1996-06-14 | 2004-06-01 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
WO1997047192A1 (en) * | 1996-06-14 | 1997-12-18 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
US6361933B1 (en) | 1996-06-14 | 2002-03-26 | Biostore New Zealand Limited | Solutions for the preservation of tissues |
US5962213A (en) * | 1996-06-14 | 1999-10-05 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
US5879875A (en) * | 1996-06-14 | 1999-03-09 | Biostore New Zealand | Compositions and methods for the preservation of living tissues |
US6040132A (en) * | 1996-06-14 | 2000-03-21 | Biostore New Zealand, Ltd. | Methods for the lyophilization of living biological materials |
US5827640A (en) * | 1996-06-14 | 1998-10-27 | Biostore New Zealand Limited | Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose |
US20040229203A1 (en) * | 1996-06-14 | 2004-11-18 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
US6114107A (en) * | 1996-06-14 | 2000-09-05 | Biostore New Zealand Limited | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues |
US6060233A (en) * | 1996-06-14 | 2000-05-09 | Biostore New Zealand, Ltd | Methods for the lyophilization of platelets, platelet membranes or erythrocytes |
AU735799C (en) * | 1997-02-28 | 2005-04-28 | Regents Of The University Of California, The | Methods and compositions for optimisation of oxygen transport by cell-free systems |
US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
AU5102698A (en) * | 1997-10-31 | 1999-05-24 | Biotime, Inc. | Physiologically acceptable aqueous solutions and methods for their use |
US6589223B1 (en) * | 1999-02-03 | 2003-07-08 | Biotime, Inc. | Method and compositions for use in perfusion applications |
US6824389B1 (en) * | 1999-03-04 | 2004-11-30 | Medical Education & Research Institute | Post mortem reconstitution of circulation |
US6492103B1 (en) * | 2000-01-31 | 2002-12-10 | Organ Recovery Systems, Inc. | System for organ and tissue preservation and hypothermic blood substitution |
MXPA03009622A (es) * | 2001-04-23 | 2005-03-07 | Amaxa Gmbh | Solucion amortiguadora para electroporacion y metodo que comprende el uso de la misma. |
US20070213793A1 (en) * | 2001-08-06 | 2007-09-13 | Radiant Medical, Inc. | Use of endovascular hypothermia in organ and/or tissue transplantations |
US20050164915A1 (en) | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
JP3912206B2 (ja) * | 2002-07-05 | 2007-05-09 | 株式会社日立製作所 | 筒内直接燃料噴射装置用燃料ポンプ |
US9237744B2 (en) * | 2004-05-26 | 2016-01-19 | National University Corporation Kagawa University | Preservative solution for cells, tissues and organs containing rare sugar and preservative method thereof |
WO2006015353A2 (en) * | 2004-07-30 | 2006-02-09 | Washington University In St. Louis | Surgical cooling system and method |
US8835104B2 (en) | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
US8288084B2 (en) * | 2009-07-12 | 2012-10-16 | Revive Organtech, Inc. | Composition and method for flushing and cold/cryo preserving organs, tissues, and cells |
WO2012139017A1 (en) | 2011-04-07 | 2012-10-11 | Fenwal, Inc. | Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates |
MX2017000438A (es) * | 2014-07-11 | 2017-08-16 | Ltd Liability Company Cardiosystempharma (Llc Csp ) | Solucion cardioplejica de propositos generales (variantes). |
EP3221859B1 (en) * | 2014-11-18 | 2020-10-21 | Maximum Fidelity Surgical Simulations, LLC | Post mortem reconstitution of circulation |
AU2018365257B2 (en) | 2017-11-13 | 2021-05-13 | Maximum Fidelity Surgical Simulations, LLC | Reconstitution of post mortem circulation, specialized methods and procedures |
US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
WO2020232402A1 (en) | 2019-05-15 | 2020-11-19 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
DE2801123C2 (de) * | 1977-01-26 | 1986-01-02 | Armour Pharma GmbH & Co KG, 3440 Eschwege | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates |
US4170597A (en) * | 1977-12-08 | 1979-10-09 | American Cyanamid Company | 1-Hydroxymethyl-1-oxo-prostane derivatives of the E2 series |
US4245121A (en) * | 1980-02-04 | 1981-01-13 | American Cyanamid Company | Prostenoic acids and esters |
US5084377A (en) * | 1984-09-19 | 1992-01-28 | Larry Rowan | Cryogenic suspension method |
US4908350A (en) * | 1985-10-31 | 1990-03-13 | The Regents Of The University Of California | Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock |
US5084558A (en) * | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
US4927806A (en) * | 1987-04-23 | 1990-05-22 | The Regents Of The University Of California | Saturated salt/concentrated dextran formulation to treat hemorrhage |
US4923442A (en) * | 1988-05-02 | 1990-05-08 | Cryomedical Sciences Inc. | Blood substitute |
US5130230A (en) * | 1988-05-02 | 1992-07-14 | Cryomedical Sciences, Inc. | Blood substitute |
US5082831A (en) * | 1989-12-05 | 1992-01-21 | Cryovita Laboratories, Inc. | Total body washout solution and method of use |
-
1992
- 1992-04-16 CA CA002066374A patent/CA2066374C/en not_active Expired - Fee Related
- 1992-04-17 ES ES92912306T patent/ES2162797T3/es not_active Expired - Lifetime
- 1992-04-17 JP JP04511145A patent/JP3133330B2/ja not_active Expired - Lifetime
- 1992-04-17 IL IL101637A patent/IL101637A/xx active IP Right Grant
- 1992-04-17 WO PCT/US1992/003240 patent/WO1992018136A1/en active IP Right Grant
- 1992-04-17 AT AT92912306T patent/ATE202937T1/de not_active IP Right Cessation
- 1992-04-17 DE DE69231929T patent/DE69231929T2/de not_active Expired - Fee Related
- 1992-04-17 EP EP92912306A patent/EP0581883B1/en not_active Expired - Lifetime
-
1993
- 1993-09-10 US US08/119,962 patent/US5574019A/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002302401A (ja) * | 2001-04-02 | 2002-10-18 | Okinawa Prefecture Deep Ocean Water Development Coop Society | 鮮度液及びその製造方法 |
JP2010531866A (ja) * | 2007-07-03 | 2010-09-30 | アキックス リミテッド | N−置換アミノスルホン酸緩衝剤を含んでなる体液増量剤 |
JP2018087154A (ja) * | 2016-11-28 | 2018-06-07 | 3C株式会社 | 保存装置および臓器移植方法 |
JP2020505351A (ja) * | 2017-01-17 | 2020-02-20 | エクスビボ パフュージョン アクチボラゲット | 臓器保存及び/又は灌流用溶液 |
US11849721B2 (en) | 2017-01-17 | 2023-12-26 | Xvivo Perfusion Ab | Methods of preparing pH-stabilized and heat-sterilized organ preservation and/or perfusion solutions |
Also Published As
Publication number | Publication date |
---|---|
CA2066374C (en) | 2002-01-29 |
DE69231929D1 (de) | 2001-08-16 |
DE69231929T2 (de) | 2002-04-11 |
EP0581883B1 (en) | 2001-07-11 |
WO1992018136A1 (en) | 1992-10-29 |
ATE202937T1 (de) | 2001-07-15 |
US5574019A (en) | 1996-11-12 |
ES2162797T3 (es) | 2002-01-16 |
IL101637A (en) | 1997-09-30 |
JP3133330B2 (ja) | 2001-02-05 |
EP0581883A4 (en) | 1995-04-19 |
IL101637A0 (en) | 1992-12-30 |
CA2066374A1 (en) | 1992-10-20 |
EP0581883A1 (en) | 1994-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3133330B2 (ja) | 代用血液及び臓器保存溶液 | |
EP0701455B1 (en) | Plasma-like solution | |
US4923442A (en) | Blood substitute | |
US5130230A (en) | Blood substitute | |
US7943292B2 (en) | Physiologically acceptable aqueous solutions and methods for their use | |
USRE34077E (en) | Blood substitute | |
WO1989010746A2 (en) | Blood substitute | |
US6300322B1 (en) | Plasma-like solution | |
TW562678B (en) | Physiologically acceptable aqueous solutions and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071124 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081124 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091124 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091124 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101124 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111124 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121124 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121124 Year of fee payment: 12 |